Lyell Immunopharma, Inc. cash flow to debt ratio of -294.20% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lyell Immunopharma, Inc.'s free cash flow has increased -7.40% from $-162.86M last year to $-150.80M, signaling increasing performance

Lyell Immunopharma, Inc.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Lyell Immunopharma, Inc.'s debt has increased relative to shareholder equity from 0.15 last year to 0.18 today, signaling weakened financials

Lyell Immunopharma, Inc. has negative EBITDA, making leverage ratio unreliable

Lyell Immunopharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Lyell Immunopharma, Inc.'s profit margin has decreased (41.36%) in the last year from -562.29K% to -794.86K%, signaling decreasing performance

Lyell Immunopharma, Inc.'s short-term assets of $260.94M exceed its short-term liabilities of $49.41M

Lyell Immunopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lyell Immunopharma, Inc.'s return on equity of -85.71%, is lower than 15.00%, indicating bad performance

Lyell Immunopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lyell Immunopharma, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Lyell Immunopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lyell Immunopharma, Inc. has negative free cash flow, indicating cash burn

Lyell Immunopharma, Inc.'s yearly earnings has increased -19.98% since last year from $-342.99M to $-274.45M, signaling increasing performance

Lyell Immunopharma, Inc.'s yearly revenue has decreased -40.98% since last year from $61.00K to $36.00K, signaling decreasing performance

ROIC -59.39% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lyell Immunopharma, Inc.'s 3-year revenue CAGR of -92.48% is negative, indicating declining revenue over the past 3 years

Lyell Immunopharma, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Lyell Immunopharma, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Lyell Immunopharma, Inc. has insufficient data to evaluate this check.

Lyell Immunopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lyell Immunopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lyell Immunopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lyell Immunopharma, Inc. has insufficient data to evaluate this check.

Lyell Immunopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lyell Immunopharma, Inc. has a price-to-book ratio of 0.93x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Lyell Immunopharma, Inc. has a price-to-sales ratio of 8.74Kx, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue